PCSA · Processa Pharmaceuticals, Inc. · Documents
$1.81
-0.05 (-2.69%)
At close · Oct 23
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 14, 2026
The latest filing states the doubt was alleviated.
“Following our acquisition of Vidya and closing of the related $200 million gross private placement (from which we received net proceeds of $183.3 million) on July 30, 2026, we believe our cash and cash equivalents will be sufficient to satisfy our cash requirements over the next 12 months and beyond. This represents a material change from what we reported in our 2025 Form 10-K that disclosed substantial doubt of our ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$5.06M
Shares
2.79M
Volume · Oct 23
35.05K
Avg daily vol (3M)
266.29K
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| DEF 14A | Processa Pharmaceuticals, Inc. completed its merger with Vidya Therapeutics, Inc. on July 28, 2026, and will ask stockholders on November 30, 2026 to approve a reverse stock split at a ratio of not less than 1-for-3 and not more than 1-for-9. | 2026-10-22 | 2026-11-30 | |
| PRE 14A | Processa Pharmaceuticals completed its merger with Vidya Therapeutics on July 28, 2026 and raised approximately $200 million; stockholders will vote on required Nasdaq issuances and equity plans. | 2026-10-09 | — | |
| S-3 | Processa Pharmaceuticals, Inc. registered up to 306,574,202 shares for resale following its Vidya Therapeutics, Inc. acquisition; Processa will receive no proceeds and expects to become Vidya Therapeutics, Inc. under ticker “VDYA” if required approvals succeed. | 2026-10-09 | — | |
| PRE 14A | Processa Pharmaceuticals completed its merger with Vidya Therapeutics on July 28, 2026, raised approximately $200 million in a private placement, and is seeking approval for a 1-for-3 to 1-for-9 reverse stock split to support Nasdaq initial listing. | 2026-10-09 | — | |
| 8-K/A | Processa Pharmaceuticals added Vidya Therapeutics’ audited financial statements for 2025 and 2024, interim statements for the six months ended June 30, 2026 and 2025, and unaudited pro forma company information for 2025 and the first half of 2026. | 2026-10-05 | 2026-07-23 | |
| 10-Q | — | 2026-08-14 | 2026-06-30 | |
| 8-K | — | 2026-08-04 | 2026-07-30 | |
| 8-K | — | 2026-07-29 | 2026-07-23 | |
| DEF 14A | — | 2026-06-18 | — | |
| 10-Q | — | 2026-05-07 | 2026-03-31 | |
| 8-K | — | 2026-04-30 | — | |
| 10-K/A | — | 2026-04-30 | 2025-12-31 | |
| 10-K | — | 2026-03-18 | 2025-12-31 | |
| 8-K | — | 2026-02-19 | 2026-02-12 | |
| 8-K | — | 2026-01-07 | 2026-01-06 | |
| 8-K | — | 2025-12-15 | 2025-12-12 | |
| 10-Q | — | 2025-11-06 | 2025-09-30 | |
| 8-K/A | — | 2025-09-16 | 2025-09-11 | |
| 8-K | — | 2025-09-12 | 2025-09-11 | |
| 8-K | — | 2025-09-10 | — | |
| 8-K | — | 2025-09-02 | — | |
| DEFA14A | — | 2025-08-25 | — | |
| 8-K | — | 2025-08-25 | — | |
| 8-K/A | — | 2025-08-14 | 2025-08-04 | |
| DEF 14A | — | 2025-08-13 | — | |
| 8-K | — | 2025-08-08 | 2025-08-07 | |
| 8-K | — | 2025-08-07 | 2025-08-04 | |
| 10-Q | — | 2025-08-07 | 2025-06-30 | |
| PRE 14A | — | 2025-07-31 | — | |
| 8-K | — | 2025-07-25 | — | |
| 8-K | — | 2025-07-18 | — | |
| 8-K | — | 2025-07-15 | — | |
| 8-K | — | 2025-07-01 | 2025-06-27 | |
| 8-K | — | 2025-06-30 | 2025-06-24 | |
| 8-K | — | 2025-06-18 | 2025-06-17 | |
| 8-K | — | 2025-06-17 | — | |
| S-1 | — | 2025-06-13 | — | |
| DEF 14A | — | 2025-05-12 | — | |
| DEFA14A | — | 2025-05-12 | — | |
| 10-Q | — | 2025-05-08 | 2025-03-31 | |
| PRE 14A | — | 2025-05-01 | — | |
| 10-K | — | 2025-03-20 | 2024-12-31 | |
| 8-K | — | 2025-02-11 | — | |
| 8-K | — | 2025-02-10 | 2025-02-04 | |
| 8-K | — | 2025-01-30 | 2025-01-27 | |
| S-1/A | — | 2025-01-27 | — | |
| S-1/A | — | 2025-01-16 | — | |
| S-1 | — | 2024-12-20 | — | |
| 8-K | — | 2024-11-06 | 2024-10-31 | |
| 10-Q | — | 2024-10-30 | 2024-09-30 |
Showing 1–50 of 174 filings